Annual Revenue Comparison: AstraZeneca PLC vs Teva Pharmaceutical Industries Limited

AstraZeneca's growth vs. Teva's decline: A decade in review.

__timestampAstraZeneca PLCTeva Pharmaceutical Industries Limited
Wednesday, January 1, 20142609500000020272000000
Thursday, January 1, 20152470800000019652000000
Friday, January 1, 20162300200000021903000000
Sunday, January 1, 20172246500000022385000000
Monday, January 1, 20182209000000018854000000
Tuesday, January 1, 20192438400000016887000000
Wednesday, January 1, 20202661700000016658000000
Friday, January 1, 20213741700000015878000000
Saturday, January 1, 20224435100000014925000000
Sunday, January 1, 20234581100000015846000000
Monday, January 1, 20245407300000016544000000
Loading chart...

Infusing magic into the data realm

AstraZeneca vs. Teva: A Decade of Revenue Dynamics

In the ever-evolving pharmaceutical industry, AstraZeneca PLC and Teva Pharmaceutical Industries Limited have showcased contrasting revenue trajectories over the past decade. From 2014 to 2023, AstraZeneca's revenue surged by approximately 75%, reflecting its strategic focus on innovative medicines and emerging markets. In contrast, Teva's revenue declined by about 22%, highlighting challenges in the generic drug market and patent expirations.

Key Insights

  • AstraZeneca's Growth: By 2023, AstraZeneca's revenue reached nearly double its 2014 figures, driven by successful product launches and expansion in oncology.
  • Teva's Challenges: Teva faced a steady decline, with 2023 revenues falling to about 78% of its 2014 levels, underscoring the impact of market pressures and restructuring efforts.

This comparison underscores the dynamic nature of the pharmaceutical sector, where strategic pivots and market adaptability are crucial for sustained growth.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025